Protein-Like Polymers for Tau Aggregation and Phase-State Control
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current approaches to inhibit or control protein misfolding diseases, such as Alzheimer's disease, have proven challenging, particularly in addressing the dysregulation and off-pathway behavior of the microtubule-associated protein tau, which is causative for tauopathies like AD and frontotemporal dementia.
Innovation Solution
The use of protein-like polymers (PLPs) that can inhibit, accelerate, bind to, or mimic tau protein, thereby engaging the cellular machinery to disrupt off-pathway aggregation and alter the biological consequences of tau protein misfolding.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If traditional small molecule or antibody approaches are used to inhibit protein misfolding, then the approach is simple and well-established, but the effectiveness in controlling tau dysregulation and aggregation has proven elusive or unsuccessful
Solution Approach 1:
The patent employs protein-like polymers (PLPs) that combine peptide side chains with polymer backbones to create composite molecular structures. These PLPs integrate the binding specificity of peptides with the structural stability and pharmacological properties of polymers, achieving effective tau aggregation control that traditional small molecules or antibodies cannot accomplish alone.
Solution Approach 2:
The invention modifies the physical and chemical parameters of tau protein interactions by introducing PLPs with specific peptide sequences and polymer characteristics. By adjusting parameters such as peptide sequence composition, polymer molecular weight, and side chain density, the PLPs effectively alter tau aggregation kinetics and morphology, providing reliable control over the disease pathway.
2Reliability
If protein-like polymers are used to engage tau and cellular machinery, then effectiveness in preventing aggregation is improved, but the complexity of the polymer structure and formulation increases
Solution Approach 1:
The PLP structure is segmented into distinct functional components: a polymer backbone providing structural framework and pharmacological properties, and peptide side chains providing specific binding affinity to tau. This segmentation allows independent optimization of each component and simplifies the overall design and formulation process despite the increased molecular complexity.
Solution Approach 2:
The PLP platform is designed to be multi-functional, capable of binding to tau in various aggregation states, engaging cellular quality control machinery, and modulating aggregation kinetics. This universal design approach allows a single polymer platform to address multiple aspects of tau pathology, reducing the need for multiple specialized compounds.
3Reliability
If PLPs are designed to bind and mimic tau protein, then the ability to engage phase-separated states and alter biological consequences is improved, but the difficulty in detecting and measuring the effects increases
Solution Approach 1:
The patent incorporates fluorescent or chromogenic tags on the PLP structure that undergo detectable changes when bound to tau or when tau undergoes phase separation. These color or fluorescence changes provide direct visual evidence of PLP-tau interaction and phase-separated state engagement, significantly easing the detection and measurement of otherwise subtle biological effects.
Data Source
AI summary
Disclosed are protein-like polymers and uses thereof. The protein-like polymers generally comprise a polymer of formula (FX1). The polymer of formula (FX1) in some aspects comprises a peptide that (i) inhibits aggregation of, (ii) accelerates aggregation of, (iii) binds to, and/or (iv) mimics: (a) at least a portion of Tau protein, and/or (b) at least a portion of microtubulin protein.